Concord Medical Services (NYSE:CCM) Stock Price Passes Above 200-Day Moving Average – Should You Sell?

Concord Medical Services Holdings Limited (NYSE:CCMGet Free Report) shares crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $4.27 and traded as high as $5.03. Concord Medical Services shares last traded at $4.50, with a volume of 125,624 shares changing hands.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Concord Medical Services in a report on Tuesday, May 26th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Read Our Latest Report on CCM

Concord Medical Services Stock Performance

The company has a current ratio of 0.48, a quick ratio of 0.46 and a debt-to-equity ratio of 1.33. The company’s 50-day moving average price is $4.64 and its two-hundred day moving average price is $4.27.

About Concord Medical Services

(Get Free Report)

Concord Medical Services Holdings Limited is one of China’s leading providers of radiotherapy equipment and oncology services. The company specializes in supplying and operating advanced radiotherapy machines, including linear accelerators, computed tomography (CT) simulators and brachytherapy units, to public and private hospitals. Through its integrated service model, Concord Medical Services delivers treatment planning, machine maintenance and clinical support to enhance the precision and effectiveness of cancer therapies.

Founded in 1997 and headquartered in Beijing, Concord Medical Services has developed an extensive network of oncology centers across major cities and provinces in China.

See Also

Receive News & Ratings for Concord Medical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concord Medical Services and related companies with MarketBeat.com's FREE daily email newsletter.